HR Execs on the Move

TruTag Technologies

www.trutags.com

 
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.trutags.com
  • 2045 Lauwiliwili Street Building 3
    Kapolei, HI USA 96707
  • Phone: 808.878.8247

Executives

Name Title Contact Details
Randy Rubenstein
 North American Sales Director Profile

Similar Companies

Merck Frosst Canada

Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PharmaSserv

PharmaSserv is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Checkpoint Surgical

Checkpoint Surgical advances the science and practice of nerve protection and repair to improve the quality of life for patients and physicians.

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.